Mone et al. reported that the SGLT2 inhibitor empagliflozin improved cognitive and physical functions [58] and mRNAs signature of endothelial dysfunction in frail diabetic patients with HFpEF [59]. This evidence concerns the gene SLC5A2 and endothelial dysfunction.